Bavarian Nordic A/S (OTCMKTS:BVNRY – Get Rating)’s stock price passed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $10.77 and traded as high as $12.29. Bavarian Nordic A/S shares last traded at $12.25, with a volume of 48,595 shares changing hands.
Bavarian Nordic A/S Stock Performance
The stock has a market cap of $2.60 billion, a P/E ratio of -28.49 and a beta of 1.56. The stock’s fifty day moving average is $10.77 and its 200 day moving average is $11.71.
Bavarian Nordic A/S (OTCMKTS:BVNRY – Get Rating) last issued its quarterly earnings data on Wednesday, November 9th. The company reported $0.01 earnings per share for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.04). Bavarian Nordic A/S had a negative return on equity of 8.53% and a negative net margin of 25.83%. The company had revenue of $135.96 million for the quarter, compared to analysts’ expectations of $153.80 million. Equities research analysts predict that Bavarian Nordic A/S will post -0.23 EPS for the current year.
About Bavarian Nordic A/S
Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases. It specializes in cancer immunotherapy which includes cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian and prostate cancer.
- Get a free copy of the StockNews.com research report on Bavarian Nordic A/S (BVNRY)
- Insulet Has Potential To Gain More Than Analysts Are Forecasting
- Cathie Wood Is Buying These Stocks, Should You?
- Tritium Is the Largest DC EV Charger Maker You’ve Never Heard Of
- Thor Industries Hammered Its Numbers. Is it a Buy?
- United Airlines Soars Ahead of Earnings…Time to Deplane?
Receive News & Ratings for Bavarian Nordic A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bavarian Nordic A/S and related companies with MarketBeat.com's FREE daily email newsletter.